Wednesday, June 19, 2019 5:23:35 PM
North Bud Capital Holdings Ltd. (“North Bud Capital”), a significant and founding shareholder of the Company, has demonstrated its commitment to the continued success of the Company by committing $1 million as the lead investor in the offering. The Company plans to use the net proceeds of the offering to hire additional staff for its Canadian operations, pursue M&A opportunities in the United States, including new state license applications, and for general working capital purposes.
“These funds are essential to fund ongoing and existing acquisition efforts in the United States,” said Ryan Brown, CEO of North Bud Farms.
The Company expects to close on the balance of the previously announced private placement of up to $4 million in one or more additional tranches of the offering in the near future, subject to the receipt of all necessary regulatory approvals. All securities issued pursuant to the offering are subject to a four-month hold period in accordance with applicable Canadian securities laws.
As previously mentioned, North Bud Capital participated in the offering by subscribing for 3,333,333 Units, representing an investment of $1 million. North Bud Capital’s participation is considered a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the formal valuation requirements and majority of the minority shareholder approval requirements of MI 61-101 contained in Section 5.5(a) and Section 5.7(1)(a) in respect of the foregoing related party transaction on the basis that the fair market value of the transaction does not exceed more than 25% of the Company’s market capitalization.
Shares for Services
The Company has also issued 129,142 common shares at a price per share of $0.35 to AGORACOM as per the September 21, 2018 press release for marketing services rendered to the Company through to June 15, 2019.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM